34 results on '"Borzilleri, Robert"'
Search Results
2. TGFβ2 and TGFβ3 mediate appropriate context-dependent phenotype of rat valvular interstitial cells
3. Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form
4. Heterobicyclic inhibitors of transforming growth factor beta receptor I (TGFβRI)
5. Long-Acting Tumor-Activated Prodrug of a TGFβR Inhibitor
6. Pharmacology of smac mimetics; chemotype differentiation based on physical association with caspase regulators and cellular transport
7. Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers
8. Development of a Stereoselective and Scalable Synthesis for the Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor, BMT-297376; N-((R)-1-((cis)-4-(3-(Difluoromethyl)-2-methoxypyridin-4-yl)cyclohexyl)propyl)-6-methoxynicotinamide
9. Conformational-Analysis-Guided Discovery of 2,3-Disubstituted Pyridine IDO1 Inhibitors
10. Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis
11. JAK Family Inhibitors for Autoimmune Diseases
12. Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy
13. Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1
14. Pharmacodynamics‐based approach for efficacious human dose projection of BMS‐986260, a small molecule transforming growth factor beta receptor 1 inhibitor
15. Design, Synthesis, and Structure–Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibody–Drug Conjugates
16. Development of a Scalable Synthesis of the Small Molecule TGFβR1 Inhibitor BMS-986260
17. Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent
18. Macrocyclic pyrrolobenzodiazepine dimers as antibody-drug conjugate payloads
19. Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology Agents
20. Discovery of tetrahydroisoquinoline-based bivalent heterodimeric IAP antagonists
21. Discovery and Synthesis of Heterobifunctional Degraders of Rearranged during Transfection (RET) Kinase
22. Decarboxylative Peptide Macrocyclization through Photoredox Catalysis
23. Building homogeneous time-resolved fluorescence resonance energy transfer assays for characterization of bivalent inhibitors of an inhibitor of apoptosis protein target
24. Ultrasensitive Quantitative LC–MS/MS of an Inhibitor of Apoptosis Protein’s Antagonist in Plasma Using Protein Target Affinity Extraction
25. Antroquinonol A: Scalable Synthesis and Preclinical Biology of a Phase 2 Drug Candidate
26. DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell–mediated antitumor immunity
27. Dimeric Macrocyclic Antagonists of Inhibitor of Apoptosis Proteins for the Treatment of Cancer
28. The Discovery of Macrocyclic XIAP Antagonists from a DNA-Programmed Chemistry Library, and Their Optimization To Give Lead Compounds with in Vivo Antitumor Activity
29. Discovery of Potent Heterodimeric Antagonists of Inhibitor of Apoptosis Proteins (IAPs) with Sustained Antitumor Activity
30. Decarboxylative Peptide Macrocyclization through Photoredox Catalysis.
31. The Discovery of MacrocyclicXIAP Antagonists froma DNA-Programmed Chemistry Library, and Their Optimization To GiveLead Compounds with in Vivo Antitumor Activity.
32. Discovery of Potent HeterodimericAntagonists of Inhibitorof Apoptosis Proteins (IAPs) with Sustained Antitumor Activity.
33. Antroquinonol A: Scalable Synthesis and Preclinical Biology of a Phase 2 Drug Candidate
34. Decarboxylative Peptide Macrocyclization through Photoredox Catalysis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.